Literature DB >> 23465143

Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.

Yun-Sok Ha1, Amirali Salmasi, Michael Karellas, Eric A Singer, Jeong Hyun Kim, Misop Han, Alan W Partin, Wun-Jae Kim, Dong Hyeon Lee, Isaac Yi Kim.   

Abstract

OBJECTIVE: To compare the clinicopathologic findings of African-American (AA) and White-American (WA) men with prostate cancer (PCa) who were candidates for active surveillance (AS) and underwent radical prostatectomy (RP).
METHODS: Prospectively maintained database of men who underwent RP from 2 academic centers were analyzed retrospectively. Postoperative pathologic characteristics of patients who met the AS inclusion criteria of the University of California, San Francisco (UCSF) and National Comprehensive Cancer Network (NCCN) were evaluated. After RP, the rate of pathological upstaging and Gleason upgrading were compared between AA and WA men.
RESULTS: In the AA cohort, 196 and 124 men met the UCSF and NCCN criteria for AS, respectively. With respect to WA patients, 191 and 148 fulfilled the AS criteria for UCSF and NCCN, respectively. AA men had a higher percentage of maximum biopsy core than WA men (15.3%-20.4% vs 11.5%-15.0%, P <.05, respectively) in both cohorts. In addition, a greater proportion of AA men had multiple positive biopsy cores compared to WA men (45.2% vs 33.1%, P = .046) under the NCCN criteria. A higher proportion of AA men were upstaged (≥pT3) compared to WA men (19.4% vs 10.1%, P = .037). A multivariate regression test revealed that age, preoperative PSA, and number of positive cores were independent predictors of more advanced disease (upstaging and/or upgrading) in AA men.
CONCLUSION: AA men who were candidates for AS criteria had worse clinicopathological features on final surgical pathology than WA men. These results suggest that a more stringent AS criteria should be considered in AA men with prostate cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23465143      PMCID: PMC3978180          DOI: 10.1016/j.urology.2012.12.046

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  20 in total

1.  Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.

Authors:  Guillaume Ploussard; Alexandre de la Taille; Stéphane Terry; Yves Allory; Idir Ouzaïd; Francis Vacherot; Claude-Clément Abbou; Laurent Salomon
Journal:  Urol Oncol       Date:  2012-01-31       Impact factor: 3.498

2.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Authors:  Isaac J Powell; Cathryn H Bock; Julie J Ruterbusch; Wael Sakr
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

3.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

4.  Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.

Authors:  Patrick Mufarrij; Alex Sankin; Guilherme Godoy; Herbert Lepor
Journal:  Urology       Date:  2010-05-21       Impact factor: 2.649

5.  Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.

Authors:  Dong Il Kang; Thomas L Jang; Jeongyun Jeong; Eun Young Choi; Kelly Johnson; Dong Hyeon Lee; Wun-Jae Kim; Isaac Yi Kim
Journal:  Asian J Androl       Date:  2011-07-25       Impact factor: 3.285

6.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

7.  Survival in blacks and whites after treatment for localized prostate cancer.

Authors:  J E Fowler; F Terrell
Journal:  J Urol       Date:  1996-07       Impact factor: 7.450

8.  Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?

Authors:  Gary D Grossfeld; David M Latini; Tracy Downs; Deborah P Lubeck; Shilpa S Mehta; Peter R Carroll
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

9.  Black-white differences in the stage at presentation of prostate cancer in the District of Columbia.

Authors:  S C Ndubuisi; V Y Kofie; J Y Andoh; E M Schwartz
Journal:  Urology       Date:  1995-07       Impact factor: 2.649

10.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Authors:  Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

View more
  20 in total

1.  Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Authors:  Michael S Leapman; Stephen J Freedland; William J Aronson; Christopher J Kane; Martha K Terris; Kelly Walker; Christopher L Amling; Peter R Carroll; Matthew R Cooperberg
Journal:  J Urol       Date:  2016-06-25       Impact factor: 7.450

2.  Prostate cancer: active surveillance in African American men.

Authors:  Judd W Moul
Journal:  Nat Rev Urol       Date:  2013-05-07       Impact factor: 14.432

3.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

Review 4.  Active surveillance in men with low-risk prostate cancer: current and future challenges.

Authors:  Christopher Sejong Han; Jaspreet Singh Parihar; Isaac Yi Kim
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

5.  Biparametric MRI prior to Radical Radiation Therapy for Prostate Cancer in a Caribbean Population: Implications for Risk Group Stratification and Treatment.

Authors:  Maria A Gosein; Dylan Narinesingh; Shastri Motilal; Adrian P Ramkissoon; Cristal M Goetz; Kristy Sadho; Murrie D Mosodeen; Renee Banfield
Journal:  Radiol Imaging Cancer       Date:  2020-07-31

Review 6.  Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.

Authors:  M I Gökce; D Sundi; E Schaeffer; C Pettaway
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-04-18       Impact factor: 5.554

Review 7.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

8.  Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.

Authors:  Debasish Sundi; Oleksandr N Kryvenko; H Ballentine Carter; Ashley E Ross; Jonathan I Epstein; Edward M Schaeffer
Journal:  J Urol       Date:  2013-06-14       Impact factor: 7.450

9.  Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.

Authors:  Tyler J Nelson; Juan Javier-DesLoges; Rishi Deka; P Travis Courtney; Vinit Nalawade; Loren Mell; James Murphy; J Kellogg Parsons; Brent S Rose
Journal:  JAMA Netw Open       Date:  2021-05-03

10.  Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.

Authors:  Timothy P Quinn; Martin G Sanda; David H Howard; Dattatraya Patil; Christopher P Filson
Journal:  Cancer       Date:  2021-06-17       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.